The study, led by Mohammed Khaled Al Alaili, took an unusually rigorous approach for an overview of this kind. The researchers systematically searched five databases to identify reviews of N-acetylcysteine that met predetermined inclusion and exclusion criteria, ultimately retrieving 140 separate reviews spanning the full breadth of clinical medicine. Rather than simply cataloguing these publications, the team extracted comprehensive data to map the evidence, and then applied two validated appraisal tools to assess methodological quality and risk of bias. This allowed them to stratify the evidence by how much confidence clinicians and researchers should actually place in it, a step that many broader reviews skip entirely.

One of the most striking findings concerns the hierarchy of evidence itself. Of the 140 reviews retrieved, only 63 were systematic reviews with meta-analysis, the design widely regarded as the highest level of synthesized evidence in medicine. The remainder were narrative or other less structured reviews, which are more vulnerable to selective citation and author bias. Among the 63 top-tier syntheses, roughly half supported repurposing N-acetylcysteine for new indications, a proportion that sounds encouraging until it is set against the quality appraisals. The critical appraisal revealed a high prevalence of critically low-quality systematic reviews, even as a notable proportion of reviews showed low risk of bias, a mismatch that underscores how uneven the field really is.

To quantify redundancy, the researchers calculated the corrected covered area, a metric designed to detect when multiple reviews cover the same primary studies, inflating the apparent volume of evidence without adding new information. The CCA analysis demonstrated substantial overlap and redundancy across domains, and particularly within subdomains. In practical terms, many of the 140 reviews were re-analyzing the same small pools of trials, a pattern the authors describe as possible research waste. This finding matters beyond N-acetylcysteine: it illustrates a systemic problem in evidence synthesis, where the incentive to publish reviews outpaces the production of new primary trials capable of settling clinical questions.

The biological case for repurposing N-acetylcysteine rests on its remarkable pleiotropy. Most frequently reported in the literature are its antioxidant properties: the drug replenishes glutathione, the cell’s principal endogenous antioxidant, thereby buffering the oxidative stress implicated in conditions ranging from neurodegeneration to chronic kidney disease. Alongside this, the review catalogued well-supported anti-inflammatory effects and an increasingly studied role in modulating glutamatergic signaling, the neurotransmitter system implicated in compulsive behavior, addiction, and several psychiatric disorders. Beyond these three headline mechanisms, the authors note that several additional mechanisms have been proposed, reflecting the molecule’s involvement in fundamental cellular pathways rather than any single disease-specific target.

The geographic and temporal patterns in the literature are equally revealing. The number of N-acetylcysteine reviews has increased over time, mirroring the broader surge of interest in drug repurposing and oxidative stress as therapeutic frontiers. Most of these reviews originated from China and the United States, a concentration that may shape which questions get asked and which patient populations the evidence reflects. Drug repurposing has become one of the most attractive strategies in pharmaceutical research because established agents come with known safety profiles, existing manufacturing capacity, and often low cost, and N-acetylcysteine exemplifies all three advantages, making the gap between research enthusiasm and clinical implementation all the more conspicuous.

From the mapped landscape, five clinical domains emerged as priorities for future exploration: psychiatry, reproductive medicine, nephrology, pulmonology, and toxicology. Each of these fields has plausible mechanistic rationale for benefit. In psychiatry, glutamatergic modulation offers a testable pathway for disorders of compulsion and mood. In reproductive medicine, oxidative stress is a recognized contributor to fertility problems and pregnancy complications. In nephrology and pulmonology, antioxidant and anti-inflammatory actions align with the pathophysiology of chronic organ injury, while toxicology already has one firmly established use, the treatment of paracetamol poisoning, that demonstrates the drug can change outcomes decisively when the evidence is strong enough.

What holds the field back, according to the review, is not a shortage of hypotheses but a shortage of certainty. The overall inconsistency in review certainty remains a barrier to integrating N-acetylcysteine into clinical guidelines, because guideline committees require consistent, high-quality evidence before recommending a therapy for new indications. A landscape in which half of the top-tier reviews support repurposing while a large share of all reviews are critically low in quality gives committees little to work with. The redundancy documented by the CCA analysis compounds the problem, since overlapping syntheses can create an illusion of consensus where the underlying trial base is thin, heterogeneous, or outdated.

The authors argue that the way forward requires precision medicine approaches to guide future clinical implementation and research. Rather than testing N-acetylcysteine as a one-size-fits-all intervention, future trials could stratify patients by oxidative stress burden, genetic determinants of glutathione metabolism, or disease subtype, identifying the populations most likely to benefit. Such targeting could also resolve some of the heterogeneity that has plagued meta-analyses, in which mixed patient groups and variable dosing regimens make pooled estimates difficult to interpret. By delineating research priorities and highlighting new avenues, the review functions as both a map of what is known and a checklist of what must be done before the drug’s promise can be translated into practice.

For clinicians and patients, the immediate takeaway is one of cautious patience. N-acetylcysteine remains a valuable and well-established therapy in its approved roles, particularly in airway disease and acetaminophen toxicity, and its safety record makes further study attractive. But the new analysis makes clear that the sprawling literature celebrating its potential has outpaced the rigorous trials needed to confirm it. The review’s contribution is to convert that sprawling enthusiasm into an organized agenda: prioritize the five highest-potential domains, replace redundant reviews with well-designed primary trials, and apply the same methodological scrutiny to repurposing evidence that regulators demand for novel drugs. If that agenda is followed, a molecule first synthesized in the nineteenth century may yet find a second, better-evidenced life in twenty-first-century medicine.

Subject of Research: Drug repurposing potential and evidence quality of N-acetylcysteine across clinical domains

Article Title: Repurposing landscape of N-acetylcysteine: A scoping review of reviews toward clinical translation

Article References: Al Alaili, M. K. (2026). Repurposing landscape of N-acetylcysteine: A scoping review of reviews toward clinical translation. PLOS One, 21(10), e0360434. https://doi.org/10.1371/journal.pone.0360434

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0360434

Keywords: N-acetylcysteine, drug repurposing, scoping review, oxidative stress, systematic reviews, glutathione, evidence quality, research waste, psychiatry, reproductive medicine, nephrology, toxicology

The team targeted a domain where the need for agile evidence synthesis is particularly acute: randomized controlled trials (RCTs) that rely on digital health technologies. From wearable activity trackers and smartphone-based interventions to telehealth platforms and remote monitoring sensors, digital tools have multiplied the ways clinical trials collect and report outcomes. That proliferation has outpaced the reporting guidelines designed to standardize trial publication, most notably CONSORT, the widely adopted checklist that establishes common data elements for trial reporting. When researchers attempt to pool results across digital health trials, they routinely encounter substantial heterogeneity in how outcomes are described, measured, and tabulated.

This reporting heterogeneity is more than an inconvenience. Systematic reviews depend on the ability to locate and compare consistent data elements across dozens or hundreds of primary studies. When a trial reports its engagement metrics in one format and its equity-related participant characteristics in another, or omits key technology-adherence details altogether, reviewers must either exclude the study or spend additional time hunting through supplementary materials. The authors argue that machine-assisted evaluation of reporting adherence offers a pathway toward more nimble information management, one that can accommodate the diverse and disruptive nature of technology-enabled trials as they emerge.

The framework the researchers propose follows a two-stage logic that mirrors how human reviewers work, but compresses the timeline dramatically. In the retrieval stage, the large language model performs article screening, deciding which candidate publications meet inclusion criteria for a given review question. In the abstraction stage, the model handles text and table preprocessing and then conducts full-text review, extracting the specific data elements the reviewers need. Crucially, the approach relies on an unmodified pretrained model, meaning the researchers did not train or fine-tune the model on annotated medical literature. Instead, they designed prompts and workflows that steer the general-purpose model toward reliable performance on specialized tasks.

To test the framework, the team ran two case studies, each examining adherence to a different set of reporting guidelines in digital health technology-enabled RCTs. The first case study evaluated how well trials reported technology-related outcomes, such as measures of participant engagement with the digital intervention. The second focused on digital health equity reporting items, which capture whether trials describe how their technologies perform across diverse populations, including groups that have historically been underrepresented in digital health research. Both case studies were chosen because they represent areas where reporting practices remain inconsistent and where automated assessment could deliver immediate practical value.

The performance results are the study’s headline finding. Across both screening and information-extraction tasks, the large language model achieved F1 scores of at least 0.9, a level the authors describe as on par with inter-annotator agreement, the benchmark that measures how well two trained human reviewers agree with each other on the same tasks. In practical terms, this means the model’s judgments about which articles to include and its extractions of specific data points from full texts were as consistent with a reference standard as a second human expert would typically be. For a tool that requires no custom training, that level of agreement represents a meaningful threshold for real-world deployment.

The implications extend well beyond the two case studies. Systematic reviews of RCTs underpin clinical practice guidelines, regulatory decisions, and health technology assessments, yet the volume of published trials continues to grow faster than the workforce available to review them. A framework that can reliably automate screening and abstraction could shorten the lag between the publication of primary evidence and its incorporation into synthesized knowledge. In digital health specifically, where interventions and technologies evolve on timescales of months rather than years, that acceleration could determine whether reviews remain relevant by the time they are published.

The study also carries a pointed message for trial investigators and journal editors. The authors demonstrate the importance of common reporting elements across digital health technology-enabled RCTs, and their automated assessment of reporting adherence makes gaps visible at scale. If a machine can rapidly quantify how consistently trials report technology engagement or equity-related items, then funders, guideline developers, and editorial boards gain a new instrument for monitoring compliance and identifying where CONSORT extensions or digital-health-specific checklists need strengthening. Better reporting, in turn, feeds back into better synthesis, creating a virtuous cycle that the framework is positioned to support.

Methodologically, the retrieval-to-abstraction design reflects a broader shift in how researchers are approaching large language models in scientific workflows. Rather than building bespoke models for each task, the authors show that a single pretrained model, guided by carefully structured prompts and pipeline stages, can handle the heterogeneous formats found in real published literature, including the tables and supplementary text where trial outcomes often hide. The preprocessing steps that convert raw text and tables into model-readable inputs are a key part of the pipeline, addressing one of the persistent obstacles to automating literature review: the sheer variability of how information is presented across journals and study designs.

Cautious optimism seems the appropriate stance. The study reports case demonstrations in a specific domain rather than a comprehensive validation across all of medicine, and the authors frame their findings as supporting the scalability and rigor of accelerated evidence synthesis, not as proof that human reviewers are obsolete. Human expertise remains essential for defining review questions, adjudicating ambiguous cases, and interpreting clinical significance. But the demonstration that an unmodified large language model can match inter-annotator agreement on both screening and extraction in digital health trial reviews marks a tangible step toward a future in which the evidence base for clinical decisions is updated as quickly as the technologies it evaluates. As digital health continues to reshape how trials are run, the tools for reading those trials may finally be catching up.

Subject of Research: Large language model-assisted literature synthesis for evaluating reporting adherence in digital health technology-enabled randomized controlled trials

Article Title: Retrieval-to-abstraction LLM-assisted literature synthesis: Case demonstrations in digital health technology-enabled randomized controlled trial outcome reporting

Article References: Harrison, T. B., Hu, D., Jia, H., Tan, S. H., Chen, F., Zhang, Z., Lu, Q., Wang, J., Wang, L., Huang, M., Prokop, L. J., Hoy, M., St. Sauver, J., Fu, S., & Liu, H. (2026). Retrieval-to-abstraction LLM-assisted literature synthesis: Case demonstrations in digital health technology-enabled randomized controlled trial outcome reporting. PLOS Digital Health, 5(10), e0001768. https://doi.org/10.1371/journal.pdig.0001768

Image Credits: AI Generated

DOI: 10.1371/journal.pdig.0001768

Keywords: large language models, systematic reviews, randomized controlled trials, digital health, CONSORT reporting guidelines, evidence synthesis, natural language processing, clinical trial reporting, digital health equity, information extraction, article screening, PLOS Digital Health

The study, formally titled Time-to-expiration for evidence bodies of medication harms, or TIME, is the first empirical attempt to quantify how safety evidence on medications shifts over time. Systematic reviews and meta-analyses are the cornerstones of evidence-based medicine, pooling results from many randomized controlled trials to produce a single, more precise estimate of an effect. But these pooled conclusions are not carved in stone. As new trials are published, the cumulative estimate can drift, sometimes changing direction, sometimes losing or gaining statistical significance, and sometimes swinging dramatically in magnitude. Prior research has mapped how conclusions of systematic reviews evolve in general, but no one had systematically measured this phenomenon specifically for drug harms, an area where instability can directly affect prescribing decisions, regulatory warnings, and patient counseling.

To build their cohort, the researchers turned to the SMART Safety dataset, a well-established empirical resource designed for evidence synthesis of medication-related harms. From this resource they identified 505 eligible meta-analyses covering 310 distinct harm outcomes, with a median of 328 adverse events captured per meta-analysis. Rather than treating each meta-analysis as a static snapshot, the team adopted a dynamic, cumulative approach. For each meta-analysis, they aggregated trial-level two-by-two data year by year, and applied the IVhet model, an inverse-variance heterogeneity model designed to produce robust pooled effect estimates in the presence of between-study heterogeneity. This generated a running sequence of cumulative odds ratios over time, starting from the first-year cumulative estimate and extending forward as new evidence accumulated annually.

The analytical framework borrowed a tool from a very different corner of medicine: survival analysis. Just as oncologists track time to death or disease progression, the researchers tracked time to two distinct statistical events. The first was evidence expiration, defined as the first occurrence of any of three signals: a change in the direction of the effect estimate, a change in statistical significance, or a relative change of at least 50 percent in the pooled odds ratio. The second was evidence convergence, a more demanding criterion requiring that consecutive cumulative odds ratios differ by no more than 0.10 in absolute terms across five consecutive annual iterations. Using Kaplan-Meier survival curves, the team then estimated the median time to each event across the entire cohort of meta-analyses, treating each evidence body as a subject whose stability could be followed over time.

The headline finding is striking. During follow-up, signals of evidence expiration occurred in 356 of the 505 meta-analyses, or 70.5 percent of the early-stage evidence bodies examined. The median time to expiration was just three years, with a 95 percent confidence interval of three to four years. In other words, within roughly three years of the first pooled estimate being formed, the majority of harm evidence had already shifted in at least one fundamental way. Subgroup analyses across different categories of evidence showed similar patterns, with median times to expiration ranging from two to seven years depending on the subgroup. Even among the 416 meta-analyses with low heterogeneity, defined as an I-squared statistic below 50 percent, 278, or 66.8 percent, still met the expiration definition, with a median time of four years. Statistical homogeneity, it turns out, offers only modest protection against the erosion of early conclusions.

Drilling into the mechanics of expiration reveals which signals did the damage. Among the 356 expiration events, 117, or 32.9 percent, were triggered solely by a relative change of at least 50 percent in the effect magnitude, meaning the pooled odds ratio more than doubled or more than halved without necessarily flipping direction or significance. Meanwhile, 89 events, or 25.0 percent, met two or three of the expiration criteria simultaneously, indicating that a substantial minority of evidence bodies underwent wholesale transformations rather than subtle adjustments. These are not trivial statistical tremors. A 50 percent swing in an odds ratio describing a drug’s adverse effect could mean the difference between a harm considered clinically negligible and one demanding regulatory attention, or vice versa. The fact that such swings commonly occur within the first few years of an evidence body’s existence challenges the comfortable assumption that early meta-analytic findings on safety can be treated as settled.

If expiration is fast, convergence is glacial. Only 27 of the 505 early-stage evidence bodies, a mere 5.3 percent, met the convergence criterion at any point during follow-up. For those that did converge, the 5th percentile of time to convergence was nine years and the 25th percentile was 31 years, while the median could not even be estimated because so few evidence bodies reached the criterion. The practical implication is stark: the point at which a harm estimate can be considered genuinely stable, with consecutive annual estimates differing by no more than 0.10 across five consecutive years, is likely to arrive decades after the first evidence appears, if it arrives at all. Clinicians, guideline developers, and regulators are therefore operating in a prolonged window in which the evidence they rely on is both unstable and far from converged, a combination that demands explicit acknowledgment in how safety conclusions are framed and communicated.

The authors draw a direct and cautious conclusion from these patterns: early meta-analytic evidence on medication harms may expire within a relatively short time, while signals of convergence tend to appear much later, and timely updating of safety reviews should therefore be actively considered. This has cascading implications across the evidence ecosystem. Living systematic reviews, which are updated continuously as new trials emerge, suddenly look less like an administrative luxury and more like a methodological necessity for drug safety. Guideline panels that cite harm meta-analyses may need to attach explicit currency dates and reassessment triggers to their recommendations. Pharmacovigilance systems, which monitor drugs after market approval, could use expiration-style metrics to flag when accumulated evidence about a known adverse effect has shifted enough to warrant re-evaluation. The study’s framing of evidence as something with a measurable survival curve, analogous to a patient’s disease-free survival, offers a portable conceptual tool for all of these applications.

There are, of course, important nuances to keep in mind when interpreting these results. The expiration signals are statistical events, not proof that any particular clinical conclusion was wrong; a change in significance or a 50 percent shift in an odds ratio may reflect the play of chance in small early evidence bases, genuine new information from better-designed trials, or both. The convergence criterion, requiring five consecutive years of near-identical estimates, is deliberately stringent and would classify some genuinely stable evidence as not yet converged. The study also examines evidence bodies at the meta-analysis level rather than tracking individual clinical decisions, so the downstream impact on prescribing behavior remains to be studied. Still, the sheer scale of the cohort, 505 meta-analyses and 310 harm outcomes, and the consistency of the findings across subgroups lend considerable weight to the central message. Evidence on drug harms behaves less like a finished building and more like a structure under continuous renovation, and anyone who steps inside should check the inspection date.

For a field that has invested enormous effort in standardizing how evidence is produced, through PRISMA reporting guidelines, prospectively registered protocols, and GRADE certainty ratings, the TIME study adds a dimension that has largely been missing: time itself as a quality attribute of evidence. A meta-analysis published this year may carry a confidence interval, a heterogeneity statistic, and a risk-of-bias assessment, but it does not yet carry a shelf life. This research suggests it should. As the authors and their international collaborators, spanning institutions from the University of Queensland to the University of York to the University of North Carolina, make clear, the goal is not to paralyze decision-making by declaring all early evidence unreliable. It is to calibrate confidence appropriately, to update systematically and promptly, and to recognize that in the specific and consequential domain of medication harms, yesterday’s pooled odds ratio may already be yesterday’s news.

Subject of Research: Temporal stability and expiration of meta-analytic evidence on medication harms

Article Title: Time-to-expiration for evidence bodies of medication harms (TIME): survival analysis from a retrospective cohort

Article References: Wang, X., Furuya-Kanamori, L., Doi, S. A., Gu, Z., Loke, Y., Li, S., Mayo-Wilson, E., Lin, L., Golder, S., Chu, H., Vohra, S., Guo, X., & Xu, C. (2026). Time-to-expiration for evidence bodies of medication harms (TIME): survival analysis from a retrospective cohort. BMC Medicine. https://doi.org/10.1186/s12916-026-05296-8

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05296-8

Keywords: medication harms, drug safety, meta-analysis, systematic reviews, evidence expiration, evidence convergence, survival analysis, pharmacovigilance, IVhet model, odds ratio, evidence-based medicine, BMC Medicine

The study, led by Erika Renzi and colleagues including corresponding author Michele Innocenzio, is what methodologists call an overview of systematic reviews, a study of studies that sits at the very top of the evidence pyramid. Rather than examining individual trials, the team systematically gathered and analyzed reviews that had already synthesized primary research on multi-component healthcare interventions for adults aged sixty-five and older. To be included, a review had to evaluate interventions targeting older populations, which in the pooled evidence included people living with frailty, cognitive impairment, and dementia, and it had to report the use of at least one implementation theory, model, or framework, the conceptual scaffolding that researchers use to plan, execute, and evaluate the rollout of a health intervention. The search covered six major databases, including PubMed, CINAHL, Scopus, Web of Science, PsycINFO, and the Cochrane Library, from their inception through the end of December 2024, and the protocol was prospectively registered on PROSPERO under registration number CRD42023444113.

The methodological machinery behind the overview was deliberately rigorous. The authors followed the Cochrane Handbook for systematic reviews of health interventions and reported their work in line with the PRISMA 2020 statement, the international standard for transparent reporting of systematic reviews. After screening the literature, they included eight reviews in total: five systematic reviews, one systematic review with meta-analysis, and two scoping reviews. Together, these reviews covered a remarkable 16,727 older adults, giving the overview a substantial evidentiary footprint. Methodological quality of each included review was appraised with AMSTAR-2, a validated instrument for judging the reliability of systematic reviews, which allowed the team to weigh their conclusions with appropriate caution. The unit of analysis, however, was not the trials themselves but the implementation frameworks and outcome measures those reviews described.

Seven distinct implementation frameworks emerged from the analysis, and two names dominated the landscape. The first was RE-AIM, an acronym standing for Reach, Effectiveness, Adoption, Implementation, and Maintenance, which has become something of a lingua franca for researchers trying to think beyond average treatment effects and toward the practical realities of dissemination. The second was the framework developed by Proctor and colleagues, along with adaptations such as the version proposed by Peters and coworkers, which decomposes implementation into a set of discrete outcomes: acceptability, adoption, appropriateness, feasibility, fidelity, coverage, sustainability, penetration, and cost. Alongside these heavyweights, the reviews also employed process models such as Knowledge-to-Action and Knowledge Dissemination and Utilization, which describe stepwise pathways for moving research evidence into practice, as well as approaches like the Innovative Care for Chronic Conditions framework and the Continuity of Care model, which attend to the structural organization of health services around older patients.

The crucial analytical move in the overview was to map the outcomes reported across these reviews onto the implementation outcome domains defined by Proctor and colleagues and operationalized in the World Health Organization’s practical guide on implementation research. This mapping exposed a striking inconsistency. Implementation outcomes, the team found, were reported unevenly across the evidence base and were frequently inferred from proxy indicators, indirect measurements such as attendance rates or staff survey responses, rather than from instruments explicitly aligned with WHO definitions. In other words, even when researchers believed they were evaluating implementation, they were often measuring something adjacent to it, leaving readers to guess whether two studies reporting the same outcome label were actually capturing the same phenomenon.

Some outcomes fared better than others. Acceptability, the degree to which an intervention is judged agreeable and satisfactory by its recipients and providers, was the only implementation outcome consistently reported across all eight reviews, suggesting that the patient and caregiver experience is now firmly on the research agenda. Adoption, the willingness of organizations and practitioners to take up an intervention, along with coverage and sustainability, were assessed in some reviews but not others, producing a patchy picture of how often programs actually enter routine care and survive there. At the bottom of the hierarchy sat appropriateness and feasibility, each evaluated in only three of the eight reviews, and implementation costs received similarly sparse attention. These omissions matter enormously, because a program that older adults enjoy but that no clinic can afford, staff, or schedule is a program that will never reach scale.

The authors interpret this pattern as a gap between the nominal use of implementation frameworks and their consistent operationalization, a gap with two roots. The first is structural: not every framework covers the full set of implementation outcomes, so a team that adopts RE-AIM, for instance, may simply have no designated slot for measuring appropriateness or cost. The second is behavioral: primary studies apply outcome definitions inconsistently, so even when a framework does specify what should be measured, the underlying trials supply data in incompatible forms. The result is an evidence base in which the vocabulary of implementation science is widely spoken but its grammar is applied loosely, making it difficult to compare programs, aggregate findings, or draw confident conclusions about which strategies actually get multi-component interventions into the hands of older adults who need them.

Why should the general reader care about what looks like an arcane dispute over outcome definitions? Because the demographic stakes could hardly be higher. Societies across Europe, North America, and Asia are aging rapidly, and the dream of active ageing, preserving physical, cognitive, and social function deep into later life, depends on interventions that are inherently multi-component and therefore inherently complex to deliver. Frailty, cognitive impairment, and dementia are precisely the conditions where fragmented, single-domain care fails, and where coordinated programs combining exercise, nutrition, cognition, and social support show the greatest promise. Every implementation failure represents lost health for older people and wasted resources for health systems already strained by rising demand. Standardized, comparable implementation evidence is the infrastructure that would let policymakers know not just whether a program can work, but whether it will work in their hospitals, clinics, and communities.

The overview, which was supported by the Next Generation EU programme through the National Recovery and Resilience Plan as part of the AGE-IT project on ageing well in an ageing society, closes with a clear prescription rather than a shrug. The authors call for more standardized reporting of implementation outcomes, explicit alignment with the definitions set out by Proctor and colleagues and the WHO practical guide, and deliberate attention to the neglected domains of feasibility, appropriateness, and cost. They also note that reliance on proxy indicators should give way to measures that genuinely operationalize each outcome. None of this diminishes the value of the interventions themselves; instead, it reframes the challenge. The science of active ageing has largely solved the question of what to offer older adults. The next frontier, this overview makes plain, is proving, with the same rigor applied to clinical endpoints, that those offerings can actually be implemented, sustained, and scaled in the untidy reality of everyday care.

Subject of Research: Implementation science of multi-component interventions promoting active ageing in older adults

Article Title: How to ensure the implementability of multi-component interventions to improve active ageing in older people? An overview of the evidence of systematic reviews

Article References: Renzi, E., Parrinello, E., Innocenzio, M., Covelli, A., Baccolini, V., De Vito, C., Marzuillo, C., Cincotti, F., Villari, P., & Massimi, A. (2026). How to ensure the implementability of multi-component interventions to improve active ageing in older people? An overview of the evidence of systematic reviews. BMC Geriatrics. https://doi.org/10.1186/s12877-026-08325-6

Image Credits: AI Generated

DOI: 10.1186/s12877-026-08325-6

Keywords: active ageing, older adults, implementation science, systematic reviews, RE-AIM, Proctor framework, multi-component interventions, frailty, dementia, WHO practical guide, geriatrics, implementation outcomes

The urgency of this development is underscored by recent high-profile instances where systematic reviews were contaminated by inauthentic studies. A notable example involves reviews on the use of ivermectin for treating COVID-19, where several included trials were later deemed not authentic by health authorities in the United States, the United Kingdom, and the European Union. While subsequent rigorous investigations suggested little to no benefit from the treatment, the initial inclusion of dubious data had the potential to mislead clinicians and policymakers. Such incidents highlight a persistent challenge in the scientific community: problematic studies can remain unrecognized for years, and many are never formally retracted, making it difficult to determine the true scale of data integrity issues within the literature.

Historically, reviewers have relied on limited and inconsistent methods to assess the trustworthiness of trials, often focusing primarily on risk of bias or methodological quality rather than the fundamental authenticity of the data itself. This gap in assessment tools has left a window for problematic studies to persist in the literature without rigorous scrutiny. The INSPECT-SR framework was developed to fill this specific void, providing a rigorously tested and systematic approach that goes beyond traditional quality checks. By focusing explicitly on the trustworthiness of trial data, the tool enables researchers to identify a wide range of issues, from human error to potential research misconduct, without necessarily assuming deliberate wrongdoing in every case.

Developed by a collaborative team of researchers from the University of Manchester, Cochrane, and the University of Colorado, in partnership with more than 40 institutions worldwide, INSPECT-SR represents a major collective effort to standardize integrity assessments. The tool guides reviewers through 21 structured checks organized across four key domains: post-publication notices, study conduct, governance and transparency, and the analysis of text, figures, and study results. This comprehensive structure ensures that reviewers do not overlook subtle red flags that might indicate deeper problems with a study’s validity. The systematic nature of the checks allows for consistent application across different types of trials and research contexts, reducing the variability that has previously plagued integrity assessments.

Dr. Jack Wilkinson, the lead researcher on the project, emphasized the extensive expertise behind the tool’s creation. He noted that more than 150 integrity and health research experts from around the world contributed to the development of INSPECT-SR, ensuring that the framework reflects a broad consensus on best practices for detecting problematic studies. This wide-ranging collaboration lends significant credibility to the tool, positioning it as a resource that can be trusted by the global systematic review community. The involvement of such a diverse group of experts also ensures that the tool is applicable across different healthcare systems and research environments, enhancing its utility for international research teams.

Unlike existing tools that assess risk of bias or methodological quality, INSPECT-SR is specifically designed to evaluate the trustworthiness of the data presented in randomized controlled trials. This distinction is crucial because a study can be methodologically sound in its design yet still produce unreliable data due to errors or manipulation. By focusing on the integrity of the data itself, INSPECT-SR allows reviewers to identify fraudulent studies alongside other problematic trials that may result from less malicious causes, such as clerical errors or misreporting. The framework does not assume misconduct or imply deliberate wrongdoing, but it provides the mechanisms necessary to uncover such issues when they are present, thereby safeguarding the scientific record from both intentional and unintentional errors.

Lisa Bero, a fellow author from the University of Colorado and the Cochrane Senior Research Integrity Editor, highlighted the importance of this new tool for maintaining the credibility of systematic reviews. She stated that systematic reviews are only as credible as the studies they include, and INSPECT-SR provides a rigorous, thoroughly tested, and transparent way to detect problematic trials. This capability is essential for safeguarding the integrity of the evidence that informs patients, clinicians, and policymakers. By equipping reviewers with a standardized tool, the research team aims to reduce the likelihood of flawed studies influencing clinical guidelines, thereby protecting public health and ensuring that medical decisions are based on reliable data.

INSPECT-SR is freely available for anyone to use from its launch, removing financial barriers to accessing this critical resource. It has already been endorsed for use in Cochrane reviews and has been added to the resources that Cochrane review teams draw on when assessing whether included studies raise integrity concerns. This immediate integration into a major systematic review organization signals a strong endorsement of the tool’s value and practicality. The availability of the tool to all researchers, regardless of institutional affiliation or funding, ensures that the benefits of improved integrity assessment are widely distributed, potentially leading to a more robust and reliable global evidence base for medical research.

The adoption of INSPECT-SR by reviewers, guideline developers, and publishers is encouraged by the research team, who anticipate that it will become the standard for assessing the trustworthiness of randomized controlled trials. As the volume of clinical trial data continues to grow, the need for efficient and effective tools to ensure data integrity becomes increasingly important. INSPECT-SR offers a solution that is both comprehensive and accessible, providing a clear pathway for identifying and addressing problematic studies. By standardizing the assessment process, the tool helps to reduce the subjective variability that can arise when different reviewers apply different criteria, ultimately leading to more consistent and reliable systematic reviews.

The publication of INSPECT-SR in The BMJ marks a significant milestone in the ongoing effort to improve the quality and integrity of medical research. As the scientific community continues to grapple with the challenges of data integrity, tools like INSPECT-SR provide essential support for maintaining the trustworthiness of the evidence that underpins clinical practice. By enabling the early detection of problematic trials, the tool helps to prevent the distortion of evidence that can have far-reaching consequences for patient care and public health. The collaborative development and widespread availability of INSPECT-SR reflect a collective commitment to upholding the highest standards of research integrity, ensuring that the evidence base for medical decision-making remains robust and reliable for years to come.

Subject of Research: Development and application of the INSPECT-SR tool for assessing the trustworthiness of randomized controlled trials in systematic reviews.

Article Title: New tool helps researchers spot problematic trials before they distort evidence

Article References: New tool helps researchers spot problematic trials before they distort evidence. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: systematic reviews, research integrity, randomized controlled trials, data trustworthiness, Cochrane, clinical evidence, study misconduct, medical research, INSPECT-SR, evidence-based medicine, tool, helps

The motivation behind Polaris reflects a well-documented problem in evidence synthesis. Literature reviews are essential across disciplines: in the health sciences they track rapidly evolving methods of human care, in geography they have shaped frameworks from economic geography to the geography of poverty, and in interdisciplinary fields such as climate science they assess impacts on ecosystems and social inequalities. There are at least fourteen recognized review typologies, ranging from rapid and scoping reviews to full systematic reviews with meta-analysis. Yet conducting any of them well is time-consuming, particularly during bibliographic database searches, supplementary searches, and the review of each retrieved manuscript for inclusion or exclusion. Existing software such as Covidence and Rayyan helps with screening and selection, while tools like ASySD, Deduklick, BibexPy, and the Systematic Review Accelerator handle deduplication and bibliographic processing. Polaris deliberately targets a different stage: retrieval itself, the point where bias and errors most easily creep in.

Bias in literature searching can arise from the researcher’s own decisions, including selective choices of databases, filters, and search terms. When the systematic process behind a review is not fully disclosed, reproducibility suffers. Errors, meanwhile, can stem from technical and procedural limitations during data retrieval: incomplete metadata, missing author information, export restrictions, or, in the case of Google Scholar, the requirement to visit each paper’s website individually to download metadata. To combat these problems, the developers grounded Polaris in established methodological guidance. The tool follows the eight-stage model of literature searching described by Cooper and colleagues, and it aligns with the PRISMA framework, the widely adopted set of twenty-seven recommendations for reporting systematic reviews and meta-analyses. By standardizing retrieval, automating exports, preserving query logs, and improving the auditability of searches, Polaris aims to reduce potential bias and errors before screening even begins.

Technically, Polaris 1.0 is implemented in R, requiring version 4.5.1 or higher, and built on packages including httr, lite, dplyr, stringr, purrr, xml2, zip, and httr2. The architecture has two layers. The front end is a graphical user interface built with the R Shiny package, where users configure search parameters and monitor progress in real time. The back end is a processing engine with an additional asynchronous execution layer to support long-running searches, organized into modular components for software environment configuration, directory and file handling, database-specific retrieval functions, and the core engine. Users supply their queries in a simple TXT file, select the desired databases, and the software accesses each provider through its official API, retrieves the results, generates harmonized metadata, and saves each query’s output as a Research Information System (RIS) file compatible with Mendeley, Zotero, and EndNote.

Each database demands its own handling, and Polaris implements a dedicated retrieval workflow for every supported provider. PubMed is accessed through the NCBI E-utilities API in three steps: the esearch endpoint counts matching records and retrieves PubMed identifiers in batches of up to 300, the efetch endpoint collects abstracts in XML format parsed with the xml2 package, and the summary endpoint returns structured metadata including title, authors, journal, year, abstract, and DOI in JSON. No personal API key is needed, and a 0.4-second delay between requests keeps the tool compliant with PubMed policies. Scopus and ScienceDirect both rely on the Elsevier API, which requires an API key and an institutional token. Scopus queries are automatically wrapped in the TITLE-ABS-KEY field while preserving the user’s Boolean logic, and ScienceDirect searches title, abstract, keywords, and full text, with abstracts conveniently stored in the description field of the response. Semantic Scholar, which needs no key, uses a bulk search endpoint that supports Boolean expressions, with Polaris translating operators such as AND, OR, and NOT into the provider’s required syntax while preserving the logical structure of the original strategy.

A distinctive strength of the system is its three-level logging design. The first level feeds a real-time monitoring dashboard, updating users on execution status until each search completes. The second, a master log, records comprehensive metadata across all databases: the date and time each query ran, the source database, the query structure, the total number of papers retrieved, the exported RIS filename, and the search status. The third level maintains database-specific logs with the same structure. Together these logs document exactly which queries were executed, where, when, and with what results, making the entire retrieval stage auditable and reproducible. Polaris also handles Elsevier’s authentication errors gracefully: HTTP 401 and 403 errors terminate the affected request and prompt users to verify their credentials, while HTTP 429 rate-limiting responses trigger a temporary pause before retry, all displayed on the dashboard.

To demonstrate reliability, the team compared Polaris retrieval counts against the official web interfaces of PubMed, Scopus, and ScienceDirect across 60 queries, 20 per database, using identical search strings and equivalent fields. Agreement was assessed with linear regression, Pearson’s correlation, Bland–Altman analysis, and relative percentage differences. The results were striking: a Pearson correlation coefficient of r = 1.000 and a coefficient of determination R² = 1.000, with points closely following the identity line across searches ranging from a handful of records to several thousand. The Bland–Altman mean difference, or bias, was just −7.92 records, a negligible proportion for searches returning more than 5,000 results. Nearly all observations fell within the 95% limits of agreement. The mean relative difference was −0.15% and the median 0.00%, meaning most searches produced identical counts. PubMed and Scopus showed almost complete agreement, while ScienceDirect displayed a small number of larger but still limited deviations. A log-transformed Bland–Altman analysis estimated a bias of only −0.0007 log units, confirming that discrepancies do not grow with search size. The complete validation dataset and R scripts are publicly available on GitHub and archived on Zenodo.

The software does have limitations tied to each provider’s API. Without a key, PubMed caps results at 10,000 per query; ScienceDirect allows 6,000 under an API and institutional key; Scopus imposes no limit on broad retrievals; and Semantic Scholar is limited to roughly the first 300 results. Validation for Semantic Scholar was not possible because its webpage and API return different results, and for queries hitting a provider’s maximum, Polaris was considered to have correctly handled the constraint rather than achieving perfect agreement. Future versions plan to add front-end filters for year, field, and study design, along with support for the IEEE and SciELO databases to broaden coverage to engineering and Latin American literature.

Early applications suggest Polaris can scale to demanding real-world projects. In a critical review of outdoor workers and heat exposure in the United States, the software handled approximately 100,000 results drawn from multiple databases. In a systematic review of human attitudes and behavior toward snakes, queries using Boolean operators, parentheses, and asterisk truncation retrieved 21,734 records in preliminary results, demonstrating robust handling of complex syntax and special characters. Because repetitive tasks such as copying queries across platforms and manually exporting results are automated, and real-time monitoring catches interruptions during long runs, the developers argue that Polaris shifts literature retrieval from a manual, platform-dependent chore toward a standardized, traceable workflow. Its MIT-licensed R and Shiny code base makes it straightforward to adapt, extend, and reuse, potentially changing how evidence synthesis is conducted day to day in an era of ever-expanding publication volume.

Subject of Research: An automated, open-source software system for multi-database bibliographic literature retrieval supporting reproducible systematic reviews

Article Title: Polaris – an automated literature retrieval system

Article References: Polaris – an automated literature retrieval system. (n.d.). https://doi.org/10.1016/j.softx.2026.103024

Image Credits: AI Generated

DOI: 10.1016/j.softx.2026.103024

Keywords: Polaris, literature retrieval, systematic reviews, bibliographic databases, PRISMA, open-source software, R Shiny, PubMed, Scopus, ScienceDirect, Semantic Scholar, reproducibility